Health Care & Life Sciences » Pharmaceuticals | Aeolus Pharmaceuticals Inc.

Aeolus Pharmaceuticals Inc. | Balance Sheet

Fiscal year is October-September. All values USD Thousands.
2012
2013
2014
2015
2016
Cash & Short Term Investments
281.00
869.00
1,517.00
94.00
3,155.00
Total Accounts Receivable
882.00
370.00
1,559.00
1,585.00
750.00
Other Current Assets
61.00
39.00
46.00
45.00
230.00
Total Current Assets
1,224.00
1,278.00
3,122.00
1,724.00
4,135.00
Total Investments and Advances
32.00
32.00
32.00
32.00
32.00
Other Assets
-
656.00
426.00
21.00
-
Total Assets
1,256.00
1,966.00
3,580.00
1,777.00
4,167.00
ST Debt & Current Portion LT Debt
-
-
-
1,002.00
-
Accounts Payable
2,272.00
579.00
1,552.00
1,598.00
972.00
Other Current Liabilities
-
682.00
443.00
22.00
-
Total Current Liabilities
2,272.00
1,261.00
1,995.00
2,622.00
972.00
Other Liabilities
19,319.00
-
-
-
-
Total Liabilities
21,591.00
1,261.00
1,995.00
2,622.00
972.00
Common Equity (Total)
20,340.00
700.00
1,580.00
850.00
3,195.00
Total Shareholders' Equity
20,335.00
705.00
1,585.00
845.00
3,195.00
Total Equity
20,335.00
705.00
1,585.00
845.00
3,195.00
Liabilities & Shareholders' Equity
1,256.00
1,966.00
3,580.00
1,777.00
4,167.00
Preferred Stock (Carrying Value)
5.00
5.00
5.00
5.00
-

About Aeolus Pharmaceuticals

View Profile
Address
26361 Crown Valley Parkway
Mission Viejo California 92691
United States
Employees -
Website http://www.aolsrx.com
Updated 07/08/2019
Aeolus Pharmaceuticals, Inc. engages in the business of developing platform of broad-spectrum, catalytic antioxidant compounds that protect healthy tissue from the damaging effects of oxidative stress development of medical countermeasures against biological, chemical and radiological weapons in the U. S. It also develops medical countermeasures for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology.